CTLA4 and cancer: Antibodies towards programmed cell death protein and its ligand (PD-1/PD-L1) as well as cytotoxic T-lymphocyte activator-4 (CTLA-4), that boost the host’s immune system to combat a malignancy, revolutionized the landscape of cancer therapy and have been approved for a wide range of malignancies [1–3].